Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer

• Status: Unknown status
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of our current study was to analyze whether 18F-labeled Fluoromisonidazole (1-(2-nitro-1-imidazolyl)- 2-hydroxy-3-fluoropropane [18F-FMISO]) PET/CT and expression of HIF-1-alpha could predict response of primary endocrine therapy in ER-positive breast cancer

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Letrozole

Criteria

Inclusion Criteria:

1. Postmenopausal female

2. With primary invasive ER positive breast cancer pathologically approved by core needle biopsy

3. The target lesion must be measurable and maximum diameter should be over 2cm.

4. Require and accept Endocrine therapy

5. Never treated with endocrine therapy before

6. Patients must have an ECOG performance status of 0 to 2

7. Leucocyte count must be ≥ 3.0*10^9/L and platelet count must be ≥ 40*10^9/L; AST/SGOT or ALT/AGPT must be < 2 times the ULN; serum creatinine must be < 2 times the ULN

Exclusion Criteria:

1. Patients with brain and liver metastasis

2. Previous history of severe heart dysfunction (above Class III), infection, osteoporosis, bone related event or disease in endocrine system

3. Combination of other anticancer therapy, with the exception of biphosphonate